Discover a recent study, the RAIDER trial, in which 82% of patients received dose-escalated radiotherapy and experienced ...

Bladder cancer is one of the most common malignant tumors in urinary system, and the treatment faces huge challenges.

Complete removal of the bladder (cystectomy) is the treatment of choice. This provides excellent control of the primary tumor and removes all of the primary lymph node drainage and any potential ...

Prior studies have indicated that the majority of elderly patients with clinically localized muscle invasive bladder cancer do not undergo radical cystectomy as recommended by evidence-based ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

Other indications for radical cystectomy are micropapillary disease ... non-muscle-invasive bladder cancer at this time. Upper-tract evaluation is also important in the initial staging work ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

Raritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S.